Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PharmaMar Reports Positive Results for Aplidin Against Coronavirus | Contract Pharma

What are you searching for?

Sign in
Breaking News

PharmaMar Reports Positive Results for Aplidin Against Coronavirus

Therapeutic target of Aplidin (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PharmaMar has reported that results from in vitro studies of Aplidin (plitidepsin) on the human coronavirus HCoV-229E, which has a multiplication and propagation mechanism very similar to COVID-19, have been positive with a potency of the nanomolar order. These studies were conducted at the National Biotechnology Centre of the Spanish National Research Council (CSIC).

These results confirm the hypothesis that the therapeutic target of Aplidin (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus. With these data, PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with COVID-19.

In vitro, or “in glass” studies are conducted using components of an organism that have been isolated from their usual biological surroundings, such as microorganisms, cells, or biological molecules.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters